X
All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Voclosporin
Therapeutic Area: Immunology Product Name: ISA247
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Aurinia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Details:
The dedicated facility will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Lenzilumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
Details:
Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ligelizumab
Therapeutic Area: Immunology Product Name: QGE031
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ruxolitinib
Therapeutic Area: Immunology Product Name: INC424
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Novartis announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
